ClinicalTrials.gg
CompletedNCT02010216Updated Sep 25, 2014Results posted

A Study of RoActemra/Actemra (Tocilizumab) in Adult Patients With Rheumatoid Arthritis (SVOBODA Programme)

A Phase 4 interventional study of tocilizumab [RoActemra/Actemra] in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 6 sites in Kazakhstan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-25.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
95th of 110
23 · median 97
Started
2010
with 13 others
Phase 4
32 of 110
2 open now
Registered
81st of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 95th largest by enrollment, is one of 14 that started in 2010, is one of 32 in phase 4, and was the 81st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This open-label, single arm study evaluated the efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Patients received RoActemra/Actemra 8 mg/kg intravenously every 4 weeks, alone or in combination with standard anti-rheumatic therapy, for 12 weeks.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, ≥ 18 years of age
  • Confirmed moderate or severe rheumatoid arthritis
  • Intolerability or absence of effect or decrease in effect of rheumatoid arthritis treatment with disease modifying antirheumatic drugs (DMARDs)

Exclusion criteria

Exclusion Criteria:

  • Presence of infectious diseases [tuberculosis (Tb), (HIV), virus hepatitis A/B/C]
  • Inadequate hematologic, renal or liver function
  • Peptic ulcer disease (in acute phase)
  • Pregnant and lactating women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    tocilizumab [RoActemra/Actemra]

    Participants received tocilizumab 8 mg/kg by intravenous infusion every 4 weeks for 12 weeks (3 cycles).

    Drug: tocilizumab [RoActemra/Actemra]

Interventions

  • Drugtocilizumab [RoActemra/Actemra]

    Drug page: Tocilizumab

    8 mg/kg by intravenous infusion every 4 weeks

    Also known as: RoActemra/Actemra

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Disease Activity 28 (DAS28) Score

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 12

  2. Percentage of Participants Achieving ACR20/50/70 Responses After the Third Infusion Categorized by Highest Response Achieved

    American College of Rheumatology (ACR) ACR20, ACR50 or ACR70 response is defined as a ≥ 20% or 50% or 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

    Time frame: Baseline, Week 12

  3. Safety: Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)

    An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE was any experience that suggested a significant hazard, contraindication, side effect or precaution that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant.

    Time frame: 12 weeks

07

Results

Posted Sep 25, 2014

Participant flow

Participant flow — Overall Study
MilestoneTocilizumab [RoActemra/Actemra]
Started23
Completed23
Not completed0

Outcome measures

PrimaryChange From Baseline in Disease Activity 28 (DAS28) Score

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Disease Activity 28 (DAS28) Score
score on a scaleTocilizumab
Change From Baseline in Disease Activity 28 (DAS28) Score-3.9 ± 1.1
PrimaryPercentage of Participants Achieving ACR20/50/70 Responses After the Third Infusion Categorized by Highest Response Achieved

American College of Rheumatology (ACR) ACR20, ACR50 or ACR70 response is defined as a ≥ 20% or 50% or 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

Time frame:
Baseline, Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ACR20/50/70 Responses After the Third Infusion Categorized by Highest Response Achieved
percentage of participantsTocilizumab
ACR200.0
ACR509.5
ACR7066.7
PrimarySafety: Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)

An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE was any experience that suggested a significant hazard, contraindication, side effect or precaution that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant.

Time frame:
12 weeks
Reported as:
Number · participants
Safety: Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)
participantsTocilizumab
AEs5
SAEs0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab—0/23 (0%)2/23 (8.7%)
Most frequent other events
Most frequent other events
EventTocilizumab
DrowsinessNervous system disorders2/23

Baseline characteristics

Age, Continuous
Age, Continuous(years)Tocilizumab
Mean48.3 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab
Female15
Male8
08

Study locations

6 sites
  • Almaty, 050000, Kazakhstan
  • Astana, 010000, Kazakhstan
  • Astana, 010009, Kazakhstan
  • Shymkent, 160000, Kazakhstan
  • Shymkent, 160006, Kazakhstan
  • Ust-kamenogorsk, 070002, Kazakhstan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2013
First posted
Dec 12, 2013
Start
Mar 2010
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Results first posted
Sep 25, 2014
Last update
Sep 25, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02010216
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 12, 2013
Start date
Mar 2010
Primary completion
Jul 2010
Completion
Jul 2010
Results posted
Sep 25, 2014
Last update
Sep 25, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion